Zentraxa is focused on precision bioengineering to produce peptides with predictable properties tailored towards purpose. The company points out that peptides are amino acids that are the building blocks of certain proteins needed by the skin, like collagen and elastin. It has come out with a synthetic biology platform, Zentide, that designs, produces and tests novel peptides. Zentraxa argues that Zentide can circumvent previously existing bio-design limits imposed by conventional peptide synthesis and produce tailor-made biomaterials for healthcare, personal care and industrial uses. Zentraxa is initially targeting healthcare with its first biomaterial, a debondable adhesive, for use in wound care. The company asserts that the material has other uses such as cosmetics and industrial applications due to its ability to bond strongly while still being easily and painlessly removable. Zentraxa will use the investment to create a portfolio of other biomaterials for licensing to global businesses in the health and industrial sectors via its Zentide platform.
days to go:
Expired
investment:
£1,040,000
GoInStore is a first person shopping experience that allows online visitors to experience a store as if they were in the store. You are able to engage with a retail associate from that store in real-time via a one-way video stream and a two-way audio connection.
days to go:
Expired
investment:
Withheld
Network Gaming, with backing from Betfair's founder, is an inventive betting innovation company. They develop unique, responsible sports prediction products, supported by a team experienced in industry giants like FanDuel and Betfair. Their offerings help media and betting firms stand out, driving customer acquisition, while prioritizing responsible gaming and dynamic engagement.
days to go:
Expired
investment:
£250,000
ETCHO address the impact gap between investment products, wealth advisers, and end investors by providing tools to meet investor demands for impact solutions. Through a digitally friendly SaaS-base platform, they offer an impact suitability questionnaire, a proprietary inpact matching algorithm, and a research portal, helping advisers understand client suitability and recoomend aligned investments in a way that clients can easily understand and engage with.
days to go:
Expired
investment:
£300,000
Co-Space is a forward-thinking flexible office operator with a focus on affluent towns and cities outside Central London. Established in 2018, Co-Space has thrived even during the pandemic, boasting two successful sites in Reading (95% occupied) and Stevenage (93% occupied). Our approach involves transforming underutilized spaces into highly sought-after flexible offices, incorporating exceptional interior design and dedicated service. With a revenue run rate of £1.5 million and over 90% of it being contracted and recurring, Co-Space is a promising contender, bridging the gap between exceptional London design and regional competition.
days to go:
Expired
investment:
£50,000
Adapttech aim to reduce the number of sessions needed to adjust a prosthetic to it’s owner, making prosthetics more comfortable at a much faster rate. Their technology uses a laser scanner combined wearale sensors to determine where the socket needs adjustments.
days to go:
Expired
investment:
£1,225,000
Targeting heavy-duty diesel engines the Cibus21 retrofit technology system claims it is fuel-saving and reduces harmful exhaust emissions through the principle of Enhanced Combustion. With patents pending the company claims the enhanced combustion process introduces small amounts of LPG directly into the diesel engines' air intake to fundamentally change the chemistry of the combustion process. The company states that the current experienced efficiency gains are 15-20% reduced in diesel use and CO2 emissions.
days to go:
Expired
investment:
£116,000
